Pilot Study of an Implantable Microdevice for in Situ Evaluation of Drug Responses in Lung Cancer
Oliver Jonas
Summary
This research is being done to study the safety and feasibility of implanting and retrieving a microdevice that releases microdoses of 20 specific drugs or drug combinations as a possible tool to evaluate the effectiveness of several cancer drugs against lung cancer or mesothelioma. The name of the intervention(s) involved in this study are: Implantable Microdevice (IMD) Surgery (excision of tumor) Drugs used in this study will include drugs already used as standard of care for the treatment of lung cancer and mesothelioma, or other drugs that are approved or being investigated for these indications.
Description
This pilot research study is being conducted to evaluate the safety and feasibility of implanting and retrieving investigational drug-releasing microdevices in tumors of patients with lung cancer or malignant mesothelioma. The study will also explore the potential of these microdevices as a tool to assess how individual tumors respond to multiple anticancer drugs and drug combinations. The microdevices are designed to release very small quantities (microdoses) of selected anticancer drugs directly into spatially distinct regions of a tumor. The drugs evaluated may include treatments currently…
Eligibility
- Age range
- 18+ years
- Sex
- All
- Healthy volunteers
- No
Inclusion Criteria: * Patients must have the ability to understand and the willingness to sign a written informed consent document. * Participants must have confirmed or suspected lung cancer or mesothelioma or other intrathoracic malignancy, and are planned for surgical resection of the tumor as part of their standard clinical care. * Participants must be 18 years of age or older. * Participants must be evaluated by a medical oncologist or surgeon who will determine the clinically appropriate treatment strategy based on clinical history and extent of disease. * Patients must be deemed medica…
Interventions
- DrugImplantable Micro- drug delivery Microdevice (IMD)
Small, implantable device with 20 microreservoirs for drug and drug combinations, via needle, percutaneously, and guided by interventional radiologic techniques. Drugs will include selected anticancer agents, such as methotrexate, gemcitabine, pemetrexed, paclitaxel, ipilimumab, nivolumab, pembrolizumab, carboplatin, abemaciclib, vinorelbine, etoposide, and osimertinib.
Location
- Brigham and Women's HospitalBoston, Massachusetts